Skip to main content
SpringerLink
Log in

Intravenous Ibandronate in the Treatment of Osteoporosis

Profile Report

  • Adis Profile Report
  • Published:
Drugs & Aging Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I

Notes

  1. The use of trade names is for product identification purposes only and does not imply endorsement.

References

  1. Croom KF, Scott LJ. Intravenous ibandronate: in the treatment of osteoporosis. Drugs 2006; 66(12): 1593–601

    Article  PubMed  CAS  Google Scholar 

  2. Reginster J-Y. Intravenous ibandronate in the treatment of osteoporosis: a viewpoint. Drugs 2006; 66(12): 1602–3

    Article  Google Scholar 

  3. Compston J. Intravenous ibandronate in the treatment of osteoporosis: a viewpoint. Drugs 2006; 66(12): 1602–3

    Article  Google Scholar 

  4. Adami S. Intravenous ibandronate in the treatment of osteoporosis: a viewpoint. Drugs 2006; 66(12): 1602–3

    Article  Google Scholar 

  5. Roche Products Limited. Bonviva 3mg/3ml solution for injection in pre-filled syringe: summary of product characteristics (EC) [online]. Available from URL: http://www.emc.medicines.org.uk [Accessed 2006 Apr 26]

  6. Roche Laboratories Inc. Boniva® (ibandronate sodium) injection: package insert (US) [online]. Available from URL: http://www.rocheusa.com [Accessed 2006 Jul 25]

  7. Scottish Intercollegiate Guidelines Network. Management of osteoporosis: a national clinical guideline. June 2003 (updated Apr 2004) [online]. Available from URL: http://www.sign.ac.uk [Accessed 2006 Jun 12]

  8. The North American Menopause Society. Management of osteoporosis in postmenopausal women: 2006 position statement of The North American Menopause Society. Menopause 2006; 13(3): 340–67

    Article  Google Scholar 

  9. Cranney A. Treatment of postmenopausal osteoporosis: choice of treatment depends on efficacy, individual risk profile, and side effects. BMJ 2003; 327: 355–6

    Article  PubMed  CAS  Google Scholar 

  10. Chapurlat RD. Clinical pharmacology of potent new bisphosphonates for postmenopausal osteoporosis. Treat Endocrinol 2005; 4(2): 115–25

    Article  PubMed  CAS  Google Scholar 

  11. Chesnut CH, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004; 19(8): 1241–9

    Article  CAS  Google Scholar 

  12. Roche Products Limited. Bonviva 150mg film-coated tablets: summary of product characteristics (EC) [online]. Available from URL: http://www.emc.medicines.org.uk [Accessed 2006 Jun 12]

  13. Thiebaud D, Burckhardt P, Kriegbaum H, et al. Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis. Am J Med 1997 Oct; 103(4): 298–307

    Article  PubMed  CAS  Google Scholar 

  14. Adami S, Felsenberg D, Christiansen C, et al. Efficacy and safety of ibandronate given by intravenous injection once every 3 months. Bone 2004 May; 34(5): 881–9

    Article  PubMed  CAS  Google Scholar 

  15. Recker R, Stakkestad JA, Chesnut CH, et al. Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis. Bone 2004 May; 34(5): 890–9

    Article  PubMed  CAS  Google Scholar 

  16. Stakkestad JA, Benevolenskaya LI, Stepan JJ, et al. Intravenous ibandronate injections given every three months: a new treatment option to prevent bone loss in postmenopausal women. Ann Rheum Dis 2003 Oct; 62(10): 969–75

    Article  PubMed  CAS  Google Scholar 

  17. Delmas PD, Adami S, Strugala CSJA, et al. Intravenous ibandronate injections in postmenopausal women with osteoporosis. Arthritis Rheum 2006; 54(6): 1838–46

    Article  PubMed  CAS  Google Scholar 

  18. Emkey R, Zaidi M, Lewiecki EM, et al. Two-year efficacy and tolerability of intermittent intravenous ibandronate injections in postmenopausal osteoporosis: the DIVA study [abstract no. L8 plus poster]. 69th Annual Scientific Meeting of the American College of Rheumatology and the 40th Annual Meeting of the Association of Rheumatology Health Professionals: Late Breakers; 2005 Nov 12–17; San Diego (CA)

Download references

Author information

Authors and Affiliations

  1. Wolters Kluwer Health ¦ Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, Auckland, 1311, New Zealand

    Katherine F. Croom & Lesley J. Scott

  2. Editorial office of Wolters Kluwer Health, Conshohocken, Pennsylvania, USA

    Katherine F. Croom & Lesley J. Scott

Authors
  1. Katherine F. Croom
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lesley J. Scott
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Katherine F. Croom.

Additional information

Adapted and reproduced from Drugs 2006; 66 (12): 1593–1603.[1–4] The manufacturer of the agent under review was offered an opportunity to comment on the original article[1] during the peer review process; changes based on any comments received were made on the basis of scientific and editorial merit.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Croom, K.F., Scott, L.J. Intravenous Ibandronate in the Treatment of Osteoporosis. Drugs Aging 23, 997–1001 (2006). https://doi.org/10.2165/00002512-200623120-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-200623120-00006

Keywords

Search

Navigation